Peptide drug runs can stall on late raw materials, Frost & Sullivan and Medtide find
Frost & Sullivan and Medtide's 2026 white paper on peptide and oligonucleotide drugs ties contract manufacturer selection to program stage. Its sharpest point is that a late resin, amino acid or nucleotide building block can stall a campaign even with plant capacity free. Supplier depth belongs in CDMO qualification.
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Key takeaways
Open capacity at a contract manufacturer means little if a nonstandard amino acid or a modified nucleotide building block arrives late, so the supplier list deserves the same scrutiny as the capacity reservation.
What makes a good CDMO changes as a program matures: speed of problem solving decides early clinical timelines, while proven scale-up, raw-material access, reserved capacity and site-to-site transfer decide launch readiness.
A useful question for any prospective partner is which critical inputs for a given molecule already have a second qualified supplier, because switching sources later can trigger extra quality testing.
Free workspace
Turn your Sciences expertise into content.
Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.
A drug manufacturing campaign can stall with plant capacity sitting open, just because a specialized resin or a modified nucleotide building block shows up late. That's one of the most practical warnings in the 2026 Global Peptide and Oligonucleotide Drug Industry White Paper. Frost & Sullivan, a global growth consulting firm, and Medtide Inc. jointly released the report on November 20, 2026. Medtide Inc. (HKEX: 03880.HK) specializes in peptides and oligonucleotides as a contract research, development and manufacturing organization (CRDMO). It runs operations in China and the United States through two entities, Chinese Peptide Company and CPC Scientific, Inc.
The paper covers the market for these two drug families, together called TIDES, through 2030. To judge where demand is growing and which therapies could shape the market, it reviews approved products and late-stage pipelines worldwide. Its most useful part is a stage-by-stage account of what drugmakers should demand from contract development and manufacturing organizations (CDMOs). For the external manufacturing lead deciding which partner carries a molecule from clinic to launch, the useful question is what to check, and at which point in the program.
Peptides and oligos break at different points
Peptides face pressure on volume. According to the white paper, much of the recent rise in peptide sales comes from demand for GLP-1 therapies. The paper ties broad use of those therapies for diabetes and obesity to greater demand for peptide active ingredients, and that makes large-scale synthesis and purification the top priority. The difficult part is increasing output while keeping purity and yield intact.
Solid-phase synthesis is the workhorse. Liquid-phase synthesis and fragment condensation fit certain molecules, and as peptide structures get more complex, the choice of route and purification process can materially change how much usable product comes out of each batch.
Oligonucleotides face a different problem. The paper says improved delivery technology is moving development past rare diseases and into common cardiovascular and metabolic conditions, and that means larger batches. Synthesis can create impurities that closely resemble the intended sequence, which makes them difficult to detect and difficult to remove. The paper ties that challenge to the move into late-stage trials, when developers need reliable ways to identify closely related impurities and hold quality steady across larger batches. So the detection problem and the scale problem tend to show up at the same time.
Depending on the product, a manufacturer may also need to join two strands together, conjugate a targeting molecule like GalNAc, or package the drug in lipid nanoparticles. Each of those steps requires analytical methods that can still confirm identity and consistent quality at commercial scale.
Taken together, this suggests the first question should differ by molecule. For a peptide partner, ask about yield and purification throughput on structures as complex as yours. For an oligonucleotide partner, the analytical package may matter more than raw synthesis volume, because it decides whether the impurity profile can be shown to stay stable as batches grow.
Depending on the product, oligonucleotide manufacturers may also need to attach a targeting molecule such as GalNAc. Each extra step like that could mean another process to validate and another material to source as a program scales.
The supplier list is part of capacity
Peptide makers rely on inputs such as nonstandard amino acids and resins. Oligonucleotide makers may need modified nucleotide building blocks or conjugation materials that only a small number of qualified suppliers provide. The white paper notes that changing suppliers can require extra testing to show the switch doesn't affect product quality. A backup supplier only helps if it was qualified before anyone needed it. For programs that rely on those specialty inputs, supplier qualification should probably start during development rather than wait until the launch campaign is on the calendar.
Even when production capacity is available, a late specialized raw material can throw a manufacturing campaign off course. For drugmakers, that suggests a CDMO's supplier list deserves the same scrutiny as its capacity reservation. The paper describes how manufacturers manage the risk: they qualify alternative suppliers in advance, hold inventory of long-lead materials and reserve capacity for late-stage programs. It also looks at when regional manufacturing networks can keep supply moving if trade or logistics problems hit a single site or supplier.
A backup supplier only helps if it was qualified before anyone needed it.
Switching costs come down to analytics. In its section on quality, the paper says manufacturers must know three things: the impurities their process is capable of producing, how dependably their methods catch those impurities, and whether changing the process shifts the impurity profile. Moving a resin or building block to a new source is that kind of change. How strong a partner's analytical methods are could therefore determine how much testing follows a supplier swap. That bar could be harder to clear for oligonucleotides, because their impurities look very much like the intended sequence.
What changes as launch gets closer
In early development, the paper argues, the speed at which a partner solves problems can determine how quickly a program reaches its next clinical milestone. At this point a CDMO may help select a workable manufacturing route, build analytical methods and supply trial material, so issues are found before they get harder to fix at volume.
Closer to launch, the priorities shift to a proven record of scaling up, secure access to critical raw materials and the option to reserve capacity for commercial production. At that stage the paper says drugmakers need a partner that can validate the process and deliver batches that consistently meet specifications. Here the supplier question from the previous section becomes concrete. Raw-material access sits on the paper's list of late-stage priorities right next to capacity.
Launches in several markets add two more factors: experience supporting regulatory filings and transferring production between sites. The paper reviews quality expectations in the United States, Europe and China, including China's continued alignment with international standards. It also emphasizes consistent quality systems, traceable data and documented change control.
The white paper lays out a framework drugmakers can apply when qualifying a CDMO and judging whether it fits a long-term partnership:
- Initial qualification: good manufacturing practice (GMP), analytical capabilities and experience with comparable molecules.
- Approaching launch: proof of successful scale-up and technology transfer, plus reliable delivery at the needed volume.
- Before a long-term agreement: the way a CDMO reports quality deviations, how it communicates production schedule changes and how it assigns responsibility for fixing supply interruptions.
The third layer is the one most likely to get skipped, since it describes how the relationship behaves when something goes wrong, and that rarely comes up in a capability audit. Agreeing on it before a long-term contract gives both sides a shared playbook for the moment a batch slips.
Sponsors should be careful not to lean too heavily on the paper's map of providers when they decide what to buy. Among the leading names it highlights are Bachem, ST Pharm, WuXi AppTec, Nitto Avecia, PolyPeptide, CordenPharma, Agilent and Medtide. The comparison places specialist manufacturers alongside broader service providers and companies entering TIDES from adjacent businesses. It assesses each company on the molecules it supports, the span of its services from process development through commercial production, and the locations where it can make and supply products.
Those dimensions roughly track the framework's stages. Molecule coverage bears on initial qualification, service span on scale-up and transfer, and manufacturing footprint on multi-market supply. Medtide is a joint publisher of the paper and also one of the providers it features. The company says it has served more than 1,000 clients, with projects in more than 50 countries and regions. The map works best for orientation. To test any of those providers against its own molecule, a sponsor can use the framework above.
Ask a prospective CDMO which critical inputs for your molecule already have a second qualified supplier, and what quality testing a switch would trigger. The answer shows how exposed the launch is better than a capacity figure does.
Continuous purification today, continuous plants later
The report draws a line between technology already in use and technology still on the way. Automation of individual synthesis steps, continuous purification and digital batch records that trace production and quality data are already being adopted by manufacturers. Fully continuous manufacturing from start to finish is still in development, and companies are still testing whether AI can help optimize processes and predict batch outcomes.
The paper also notes that providers are investing in purification capacity. That fits its own diagnosis. Purification is where peptide yield and oligonucleotide impurity removal both run into trouble at scale, which suggests it is the step where added capacity is most likely to show up as usable output.
Solvent is the other cost of scale. Synthesis and purification can both use large volumes of it, and the paper looks at solvent recovery, waste treatment and alternative processes as ways to cut material use and disposal burden as output grows. For a sponsor drafting a supply agreement now, digital batch records and continuous purification are capabilities worth asking for by name. End-to-end continuous manufacturing belongs in roadmap conversations until a provider can show it running at commercial scale.
Sources
Featured companies
Your experts belong here
Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.
Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.
About the author
The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.